<DOC>
	<DOCNO>NCT01245140</DOCNO>
	<brief_summary>The main purpose study demonstrate improvement skin condition rate patient receive alitretinoin compare patient receive placebo .</brief_summary>
	<brief_title>Efficacy Alitretinoin Treatment Patients With Pustular Form Psoriasis</brief_title>
	<detailed_description>Palmo-plantar pustulosis ( PPP ) inflammatory skin disease affect palm sol . The disease consider sub-form psoriasis present sterile pustule palm sol . This study investigate efficacy alitretinoin patient respond topical drug ( e.g. , steroid cream ) , suffer least 6 month condition whose disease severity confirm score .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea follicle stimulate hormone concentration ≥40 international unit ( IU ) /L . Childbearing potential negative pregnancy test determine human chorionic gonadotropin ( hCG ) test screen prior dose either 1 ) agrees use medically acceptable contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point continue contraception end study , 2 ) samesex partner , prefer usual lifestyle . 2 . Capable understanding willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocol specific procedure perform . 3 . Male female age least 18 year time consent time first dose . 4 . Have PPP least 6 month , without psoriasis lesion area skin 5 . A PPPASI score least 8 involvement least 10 % palm and/or sol 6 . Refractory standard topical corticosteroid therapy 1 . Unable comply requirement study 2 . Female subject pregnant plan become pregnant breast feed 3 . Subjects whose disease adequately control standard nonmedicated therapy ( skin moisturizing protection ) 4 . Known hypersensitivity retinoids vitamin A derivative , study medication component , especially soybean oil partly hydrogenate soybean oil 5 . Treated follow treatment 4 week start study treatment : systemic drug : corticosteroid , immunosuppressant , methotrexate phototherapy : ultraviolet B light therapy [ UVB ] , psoralen ultraviolet A combination therapy [ PUVA ] , Grenz ray , Xrays 6 . Treated biologic treatment within 6 week prior start study treatment . 7 . Abnormal hematology 8 . Treated systemic topical retinoids within 3 month 1 month , respectively , start study treatment 9 . Treated highpotency topical corticosteroid within 2 week start study treatment 10 . Severe generalize pustular psoriasis 11 . A skin condition palm and/or sol interferes diagnosis PPP investigator 12 . Any condition , judgment investigator , would put subject unacceptable risk participation study . 13 . Hepatic insufficiency , severe renal failure , uncontrolled hypercholesterolemia characterize : AST/ ALT &gt; 2.5 x upper limit normal ( ULN ) Creatinine clearance &lt; 60 mL/min ( calculate , CockcroftGault ) Fasting triglyceridemia &gt; 1.5 x upper limit normal ( ULN ) Fasting cholesterol &gt; 1.5 x ULN Fasting lowdensity lipoprotein ( LDL ) cholesterol &gt; 1.5x ULN 14 . Subjects hypothyroidism indicate thyroid stimulate hormone ( TSH ) ULN thyroxine ( T4 ) test LLN hypervitaminosis A 15 . Subjects unstable cardiac disease poorly control cardiovascular risk factor , example : Acute coronary syndrome coronary revascularization ( percutaneous coronary intervention [ PCI ] , coronary artery bypass graft [ CABG ] ) within 3 month start study treatment Poorly control diabetes mellitus ( HbA1c &gt; 8.5 % ) 16 . Systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg screen examination 17 . Subjects receive drug potential drugdrug interaction , systemic tetracycline , ketoconazole , St. John 's Wort within 1 week , receive systemic itraconazole within 2 week , start study treatment 18 . Subjects include study investigational drug within 2 month start study treatment ( 3 month biologics ) 19 . Subjects score 20 Center Epidemiologic Studies Depression scale ( CESD ) , active major psychiatric disorder ( eg , Major Depressive Disorder , Generalized Anxiety Disorder , Bipolar Disorder [ I II ] , schizophrenia ) 20 . Subjects score 4 5 previous 30 day Columbia Suicide Severity Rating Scale ( CSSRS ) Screening Baseline 21 . Subjects make suicide attempt within 6 month precede Screening Baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Palmo-Plantar Pustolosis</keyword>
</DOC>